Form 4: AIM ImmunoTech Director Acquires 81,953 Shares in Open Market Purchase

Director Stewart Appelrouth purchased 81,953 shares of AIM ImmunoTech Inc. at a price of $0.193 per share on November 20, 2024.

Summary

• On November 20, 2024, Stewart Appelrouth, a director of AIM ImmunoTech Inc., acquired 81,953 shares of common stock.
• The purchase was made at a price of $0.193 per share.
• Following this transaction, Mr. Appelrouth directly owns 321,752 shares of AIM ImmunoTech Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a director buying shares is generally a good sign, it's a routine transaction and doesn't provide strong evidence of a major shift in the company's outlook.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade in their company's stock. It provides transparency into the trading activities of directors and officers.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The reporting requirements are consistent across all companies and are designed to ensure transparency in insider trading activities.
• The purchase of shares by a director is a common occurrence and is not unusual in the context of corporate governance.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

AIM ImmunoTech, insider trading, share purchase, director, stock acquisition, equity